insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro's platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience.



insitro was founded by Daphne Koller and operates through a bilingual culture – cross-functional collaboration where machine learning scientists, discovery biologists, and drug hunters work as a single integrated unit. The company established partnerships with Bristol Myers Squibb, Eli Lilly, and Gilead, and is backed by world-class investors. insitro brings together expertise across computational biology, human genetics, bioengineering, automation, and drug discovery to help bring effective medicines to patients faster.



Join us in transforming drug discovery and development!